Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.
$SYRS
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
Syros Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
87184Q206
(CUSIP Number)
September 30, 2024
(Date of Event Which Requires Filing of this Statement)
Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:
| ☒ |
Rule 13d-1(b)
|
| ☐ |
Rule 13d-1(c)
|
| ☐ |
Rule 13d-1(d)
|
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
|
Blue Owl Capital Holdings LP
|
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Delaware
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
|
515,855
|
|
|
|||
|
|
|
||||
|
6
|
SHARED VOTING POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
515,855
|
|
|
|||
|
|
|
||||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
515,855
|
|
|
|||
|
|
|
||||
|
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
|
1.92%(1)
|
|
|
|||
|
|
|
||||
|
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
|
PN
|
|
|
|||
|
|
|
||||
|
(1)
|
Calculated based on 26,832,457 shares of Common Stock outstanding as of October 24, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on
October 31, 2024.
|
| Item 1(a). |
Name of Issuer:
|
Syros Pharmaceuticals, Inc. (the “Issuer”)
| Item 1(b). |
Address of Issuer’s Principal Executive Offices:
|
35 CAMBRIDGE PARK DRIVE
CAMBRIDGE, MA, 02140
| Item 2(a). |
Names of Persons Filing:
|
This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the “Reporting Person.”
| Item 2(b). |
Address of the Principal Business Office or, if None, Residence:
|
399 Park Avenue
New York, NY 10022
| Item 2(c). |
Citizenship:
|
See response to Item 4 on the cover page.
| Item 2(d). |
Title of Class of Securities:
|
Common Stock, $0.001 par value
| Item 2(e). |
CUSIP Number:
|
87184Q206
| Item 3. |
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):
|
(e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)
| Item 4. | Ownership. |
|
|
(a)
|
Amount beneficially owned:
|
|
|
|
|
|
|
|
|
|
See response to Item 9 on the cover page.
|
|
|
|
|
|
|
|
|
(b)
|
Percent of Class:
|
|
|
|
|
|
|
|
|
|
See response to Item 11 on the cover page.
|
|
|
|
|
|
|
|
|
(c)
|
Number of shares as to which the Reporting Person has:
|
|
|
|
|
|
|
|
|
|
(i)
|
Sole power to vote or to direct the vote:
|
|
|
|
|
|
|
|
|
|
See response to Item 5 on the cover page.
|
|
|
|
|
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote:
|
|
|
|
|
|
|
|
|
|
See response to Item 6 on the cover page.
|
|
|
|
|
|
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
|
|
|
|
|
|
|
|
|
See response to Item 7 on the cover page.
|
|
|
|
|
|
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition of:
|
|
|
|
|
|
|
|
|
|
See response to Item 8 on the cover page.
|
|
|
|||
|
This Statement shall not be construed as an admission that any of the Reporting Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owners of any securities covered by this Statement.
|
|||
| Item 5. |
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that as of the date hereof the Reporting Person have ceased to be the beneficial owners of more than five percent of
the class of securities, check the following ☒.
Upon effectiveness of the Issuer’s delisting and deregistration, the Reporting Person will cease to have reporting obligations pursuant to Section 13(d).
| Item 6. |
Ownership of More than Five Percent on Behalf of Another Person.
|
Not Applicable.
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
|
Not Applicable.
| Item 8. |
Identification and Classification of Members of the Group.
|
Not Applicable.
| Item 9. |
Notice of Dissolution of Group.
|
Not Applicable.
| Item 10. |
Certification
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and
are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or
effect, other than activities solely in connection with a nomination under § 240.14a–11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Dated: November 14, 2024
|
||
|
|
BLUE OWL CAPITAL HOLDINGS LP
|
|
|
|
|
|
|
|
By:
|
/s/ Karen Hager
|
|
|
Name: Karen Hager
|
|
|
|
Title: Chief Compliance Officer
|
|